Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status

BACKGROUND: Carboplatin plus etoposide (CE) is a standard treatment for elderly patients with extensive‐disease small cell lung cancer (ED‐SCLC). However, amrubicin monotherapy (AMR) may be a feasible alternative. We compared the efficacies and safety profiles of CE and AMR for ED‐SCLC in elderly pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Igawa, Satoshi, Shirasawa, Masayuki, Ozawa, Takahiro, Nishinarita, Noriko, Okuma, Yuriko, Ono, Taihei, Sugimoto, Ai, Kurahayashi, Shintaro, Sugita, Keisuke, Sone, Hideyuki, Fukui, Tomoya, Mitsufuji, Hisashi, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Naoki, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068456/
https://www.ncbi.nlm.nih.gov/pubmed/29870153
http://dx.doi.org/10.1111/1759-7714.12772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068456/
https://www.ncbi.nlm.nih.gov/pubmed/29870153
http://dx.doi.org/10.1111/1759-7714.12772

Ejemplares similares